- Home
- CNF vs INCR Comparison
CNF vs INCR Comparison
Compare CNF & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | INCR |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.8M | 47.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNF | INCR |
|---|---|---|
| Price | $2.87 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.2K | ★ 58.9K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $252.34 | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.68 |
| 52 Week High | $24.00 | $1.77 |
Technical Indicators
Market Signals| Indicator | CNF | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 42.25 |
| Support Level | $2.93 | $0.84 |
| Resistance Level | $3.72 | $0.98 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 62.18 | 8.04 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.